Some investors have discounted Pfizer’s (NYSE: PFE) future value since the peak of the pandemic is over, but demand for continued development of COVID vaccines for future variants remains strong.
Some investors have discounted Pfizer’s (NYSE: PFE) future value since the peak of the pandemic is over, but demand for continued development of COVID vaccines for future variants remains strong.